TRAIL, Fas Ligand, TNF and TLR3 in cancer
This volume provides the current understanding of death receptor's/TLR3 signaling regulation in cancer. Death receptors, including TRAIL-R1, TRAIL-R2, Fas and TNF-RI, owing to their ability to trigger apoptosis and to contribute to the elimination of cancer cells by the immune system have been...
Saved in:
| Other Authors: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Cham :
Springer,
2017.
|
| Series: | Resistance to targeted anti-cancer therapeutics ;
v. 12. |
| Subjects: | |
| ISBN: | 9783319568058 9783319568065 9783319860060 9783319568041 |
| Physical Description: | 1 online resource |
Cover
Table of contents
| LEADER | 05792cam a2200529Ki 4500 | ||
|---|---|---|---|
| 001 | 97414 | ||
| 003 | CZ-ZlUTB | ||
| 005 | 20240914110545.0 | ||
| 006 | m o d | ||
| 007 | cr |n||||||||| | ||
| 008 | 170707s2017 sz ob 001 0 eng d | ||
| 040 | |a YDX |b eng |e pn |c YDX |d N$T |d EBLCP |d N$T |d GW5XE |d YDX |d OCLCO |d N$T |d OCLCO |d OCLCF |d NJR |d UAB |d OCLCO |d ESU |d AZU |d UPM |d IOG |d COO |d OCLCQ |d MERER |d VT2 |d OCLCQ |d OCLCO |d JG0 |d OCLCO |d OCLCA |d SNK |d U3W |d CAUOI |d KSU |d OCLCO |d OCLCQ |d AU@ |d OCLCO |d WYU |d OCLCO |d OCLCA |d OCLCQ |d OCLCO |d OCLCA |d OCLCQ |d UKAHL |d OCLCQ |d OCLCO |d UKMGB |d ADU |d LEATE |d OCLCQ |d OCLCA |d OCLCQ | ||
| 020 | |a 9783319568058 |q (electronic bk.) | ||
| 020 | |a 9783319568065 |q (print) | ||
| 020 | |a 9783319860060 |q (print) | ||
| 020 | |z 9783319568041 | ||
| 024 | 7 | |a 10.1007/978-3-319-56805-8 |2 doi | |
| 035 | |a (OCoLC)993101696 |z (OCoLC)992988865 |z (OCoLC)993555807 |z (OCoLC)1002312548 |z (OCoLC)1005791678 |z (OCoLC)1012043695 |z (OCoLC)1048139041 |z (OCoLC)1066605697 |z (OCoLC)1103271558 |z (OCoLC)1111272955 |z (OCoLC)1113447824 |z (OCoLC)1116057208 |z (OCoLC)1122846955 |z (OCoLC)1160006380 |z (OCoLC)1162794577 | ||
| 245 | 0 | 0 | |a TRAIL, Fas Ligand, TNF and TLR3 in cancer / |c Olivier Micheau, editor. |
| 260 | |a Cham : |b Springer, |c 2017. | ||
| 300 | |a 1 online resource | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a počítač |b c |2 rdamedia | ||
| 338 | |a online zdroj |b cr |2 rdacarrier | ||
| 490 | 1 | |a Resistance to targeted anti-cancer therapeutics ; |v v. 12 | |
| 504 | |a Includes bibliographical references and index. | ||
| 505 | 0 | |a Preface; Contents; Contributors; About the Editor; Chapter 1: Resistance to TRAIL Pathway-Targeted Therapeutics in Cancer; 1.1 Mechanisms of TRAIL-Induced Apoptosis; 1.1.1 TRAIL Ligand and TRAIL Receptors; 1.1.2 Engagement of the Extrinsic Pathway of Apoptosis; 1.1.3 Engagement of the Intrinsic Pathway of Apoptosis; 1.2 TRAIL's Impact on Metastasis; 1.3 Development of TRAIL Pathway-Targeted Therapeutics; 1.3.1 Optimization of TRAIL Delivery; 1.3.2 TRAIL Receptor Antibodies; 1.3.3 Small Molecules to Induce TRAIL and Upregulate DR5. | |
| 505 | 8 | |a 1.4 Mechanisms of Resistance to TRAIL Pathway-Targeted Therapeutics1.4.1 Aberration in Death Receptor Expression; 1.4.2 Strategies to Address Low Surface Levels of Death Receptors; 1.4.3 Expression of TRAIL Decoy Receptors; 1.4.4 Dysfunction in the DISC and FADD; 1.4.5 Perturbation in Downstream Pro-apoptotic Signals; 1.4.6 Strategies to Address Aberrations in Downstream Pathways of Apoptosis; 1.4.7 Resistance of Normal Cells; 1.5 Complex Nature of TRAIL Resistance; 1.5.1 Multiple Resistance Mechanisms; 1.5.2 Acquisition of Resistance. | |
| 505 | 8 | |a 1.6 Addressing Resistance to TRAIL Pathway-Targeted Therapeutics in the Clinic1.6.1 Single Agent; 1.6.2 Combinational; 1.7 Conclusion; References; Chapter 2: TRAIL-R3/R4 and Inhibition of TRAIL Signalling in Cancer; 2.1 Introduction; 2.2 The TRAIL Signalling System; 2.2.1 Structure of TRAIL; 2.2.2 Structure and Function of TRAIL Receptors; 2.2.3 TRAIL Receptor Signalling; 2.2.3.1 Apoptotic Signalling; 2.2.3.2 Necroptotic Signalling; 2.2.3.3 Non-cytotoxic Signalling; 2.2.4 TRAIL's Role In Vivo; 2.3 The TRAIL System in Cancer. | |
| 505 | 8 | |a 2.3.1 Predictive and Prognostic Significance of TRAIL Receptor Expression2.3.2 TRAIL Death Receptor Agonists; 2.3.3 The Role of TRAIL-R3 and TRAIL-R4 in Resistance to TRAIL-Mediated Apoptosis; 2.3.3.1 The Decoy Model for TRAIL-R3 and TRAIL-R4; 2.3.3.2 Formation of Heteromeric Complexes Affected in Signalling; 2.3.3.3 TRAIL-R3 and TRAIL-R4 Incorporation in Ligand Receptor Clusters; 2.3.3.4 Activation of Pro-Survival Pathways by TRAIL-R4; 2.4 Outlook; References; Chapter 3: IAPs and Resistance to Death Receptors in Cancer; 3.1 Introduction; 3.2 Structure and Molecular Functions. | |
| 505 | 8 | |a 3.3 Regulation of DR Signalling Pathways by IAPs3.3.1 Regulation of RIPK-Dependent Signalling Complex; 3.3.2 Regulation of DR-Induced Apoptosis by IAPs; 3.4 Sensitization to Death Receptor-Induced Cell Death by Smac Mimetics; 3.4.1 Smac Mimetics in Combination with Tumor Necrosis Factor (TNF); 3.4.2 Smac Mimetics in Combination with CD95; 3.4.3 Smac Mimetics in Combination with TNF-Related Apoptosis-Inducing Ligand (TRAIL); References; Chapter 4: Bcl-2 Proteins and TRAIL Resistance in Melanoma; 4.1 Apoptosis Deficiency: A Major Issue in Melanoma Therapy Resistance; 4.2 Control of Apoptosis. | |
| 506 | |a Plný text je dostupný pouze z IP adres počítačů Univerzity Tomáše Bati ve Zlíně nebo vzdáleným přístupem pro zaměstnance a studenty | ||
| 520 | |a This volume provides the current understanding of death receptor's/TLR3 signaling regulation in cancer. Death receptors, including TRAIL-R1, TRAIL-R2, Fas and TNF-RI, owing to their ability to trigger apoptosis and to contribute to the elimination of cancer cells by the immune system have been considered, to variable extent, as important therapeutic targets for cancer therapy. But an increasing body of evidence suggests that some of these receptors may also contribute to tumorigenesis, or that new players such as TLR3 may be targeted for cancer therapy due to their ability to behave like death receptors. | ||
| 590 | |a SpringerLink |b Springer Complete eBooks | ||
| 650 | 0 | |a Cancer |x Treatment. | |
| 650 | 0 | |a Apoptosis. | |
| 650 | 0 | |a Cell receptors. | |
| 650 | 0 | |a Tumor necrosis factor |x Receptors. | |
| 655 | 7 | |a elektronické knihy |7 fd186907 |2 czenas | |
| 655 | 9 | |a electronic books |2 eczenas | |
| 700 | 1 | |a Micheau, Olivier, |e editor. | |
| 776 | 0 | 8 | |i Printed edition: |z 9783319568041 |
| 830 | 0 | |a Resistance to targeted anti-cancer therapeutics ; |v v. 12. | |
| 856 | 4 | 0 | |u https://proxy.k.utb.cz/login?url=https://link.springer.com/10.1007/978-3-319-56805-8 |y Plný text |
| 992 | |c NTK-SpringerBLS | ||
| 999 | |c 97414 |d 97414 | ||
| 993 | |x NEPOSILAT |y EIZ | ||
Save to List
Cite this
Export Record
Email this